New cocktail of targeted drugs and chemo takes on pancreatic cancer
NCT ID NCT05669482
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether adding two targeted drugs (avutometinib and defactinib) to standard chemotherapy can help people with metastatic pancreatic cancer that hasn't been treated yet. About 40 adults with this cancer will receive the combination. The goal is to find the safest dose and see if it shrinks tumors or slows the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avutometinib and defactinib (targeted drugs) plus gemcitabine and nab-paclitaxel (chemotherapy)
What this could lead to
If successful, this could lead to a more effective first-line treatment for metastatic pancreatic cancer, potentially shrinking tumors and delaying disease progression.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply to all patients. The drug combination may cause significant side effects or fail to improve outcomes over standard chemo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York, 10016, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
New York Presbyterian/Weill-Cornell Medical Center
New York, New York, 10021, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Michigan Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Utah Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States